The effect of anti-IL-13 treatment on mechanism-based endpoints, for example inhibition of airway eosinophilia, are important for understanding the pharmacology of anti-IL-13 mAb and are findings consistent with IL-13 stimulating local production of the eosinophil chemoattractant eotaxin [36]. This evidence concerns the gene CCL11 and Increased total eosinophil count.